trial
as of 2026-07-01Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
NCTId NCT05962216
at a glance
Phase — · Recruiting
Enrollment 40 (estimated)
Sponsored by Dr. Albert Kar-Kin Chung
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
40 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2023-07-01
Primary completion
2026-12-31
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Dr. Albert Kar-Kin ChungLead Sponsor
Sites
1 total
Hong Kong, Hong Kong
Facts & assertions
4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2026-12-31
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
indication